about
Trial WatchTrial Watch: Adoptive cell transfer for oncological indicationsTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial watch: IDO inhibitors in cancer therapyTrial Watch: Proteasomal inhibitors for anticancer therapyTrial watch: Cardiac glycosides and cancer therapyPlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Trial watch: Immunostimulatory cytokines in cancer therapy.Quantifying time-varying cellular secretions with local linear models.State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesMeta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome.Trial Watch: Peptide-based anticancer vaccines.Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody.Classification of current anticancer immunotherapiesTrial watch: Chemotherapy with immunogenic cell death inducersTrial Watch: Immunostimulatory cytokines.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyTrial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Trial watch: Dendritic cell-based interventions for cancer therapyTrial watch: Prognostic and predictive value of the immune infiltrate in cancerTrial watch: Peptide vaccines in cancer therapyAntibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomasTrial watch: DNA vaccines for cancer therapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Trial watch: Oncolytic viruses for cancer therapyTumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastomaDendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyMonoclonal antibodies as therapeutics in human malignancies.Monoclonal antibodies against human cancer stem cells.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.Cancer immunotherapy turns viralNovel multifunctional antibody approved for the treatment of breast cancer.Immunological effects of chemotherapy in spontaneous breast cancers.Victories and deceptions in tumor immunology: Stimuvax(®)Mechanisms of monoclonal antibody stabilization and release from silk biomaterials.
P2860
Q24618653-379A0398-D382-4E4D-8CE7-8FFE8890F897Q26785545-3FC7EB40-FF2A-40C1-8226-36949C1B2330Q26993238-870F7B88-3AE1-45FE-8A6D-38339A5D94B9Q26996518-24CC3BF4-0BA8-4B31-9CD0-E95E1D7D9E1EQ27006866-D5F3CC24-E9E4-4ACC-AF0D-69B11AA309EEQ28082910-8058BC99-C102-4872-AEA8-F5ED775E36C5Q28395830-FB5874A1-6F0A-4224-AFB9-1C48A856C6E8Q30250273-4C6AC7AD-51BF-4095-B7A3-540D96FC9EB9Q33880165-CDF105B7-190A-49AC-9552-C3184A9E58E5Q33897118-61BA7621-9DBA-4586-9DCA-F2C3CC46F30FQ34045119-964D6B31-A387-4405-A8A0-763B4D9883E1Q34372945-8B00D586-7D52-4072-A18F-4606D8EB8E63Q34483345-C8D9AA2B-EF91-4D30-B67D-DA4BF38BC28DQ34859794-61EA440B-CDE8-413E-B4CA-DAB1DEF58676Q35068156-F4F18B7B-1D03-43DF-A2C1-9B01C3F032B3Q35149637-4EC45F70-A38B-4826-8D20-772A251B6A52Q36038456-6DF51FB2-0CAA-4EA3-BDF6-BA5BA955FA7CQ36057492-BEFC4E33-5D67-4179-A447-67ACCDFBDEFCQ36194849-C13DEE5A-7815-4CB0-8FAA-88886D1DE5F3Q36373370-B364B46B-BB39-4F3D-BF92-03E5BC86BD4AQ36388529-DA6D652B-016A-4F81-8EC1-F627F7DC4FD1Q36456483-DB399631-8692-4C20-992D-C5ABC57E5834Q36476100-5BD96BB0-3FCB-43D1-80B5-B6B578F14685Q36775313-768126BF-37AE-4E65-80A0-E5247B3EC0AAQ36845824-A43DA649-FFB4-4356-AF3E-687BAE3FADBFQ36887833-C91BE202-9063-4557-8ECB-B1F4D5B07AB9Q37028023-FC6C4A6B-2486-4FE8-9437-373C8D3619DEQ37028767-1287B9D2-185B-46A9-AFA3-674B57A07F71Q37078946-5FD22418-3AB5-4AA5-9473-6C85819495A2Q37629700-AFD7461D-2ABA-4D70-AE01-E20C7F8B3841Q37652790-6C4B229B-3B1F-48AA-8EB9-367924DDD2BCQ38206275-42F788E6-1EAE-47C7-90DD-8B39CEF3C0C9Q38206818-1C15F525-6CFA-42C7-B51E-EA4C02408E61Q38852051-078589CF-6D46-412E-8070-21A4149A7F71Q40004066-7E3BEE9F-4939-44C4-BDD7-F8EE95329C99Q40725853-87E027FD-873D-42BD-B7FE-B170179C2EF6Q40930170-BDEDE763-EEC7-4C42-8A33-314BB2CD862FQ41870388-27F31E99-C918-48C8-8E80-3E5E243A57ECQ41968092-7704735D-726A-42EF-9DDA-0844BA1B6452Q42007640-B8283469-F20F-40DB-860A-B6EFF0FD6E87
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Trial Watch: Monoclonal antibodies in cancer therapy
@ast
Trial Watch: Monoclonal antibodies in cancer therapy
@en
type
label
Trial Watch: Monoclonal antibodies in cancer therapy
@ast
Trial Watch: Monoclonal antibodies in cancer therapy
@en
prefLabel
Trial Watch: Monoclonal antibodies in cancer therapy
@ast
Trial Watch: Monoclonal antibodies in cancer therapy
@en
P2860
P50
P356
P1433
P1476
Trial Watch: Monoclonal antibodies in cancer therapy
@en
P2860
P356
10.4161/ONCI.1.1.17938
P50
P577
2012-01-01T00:00:00Z